20 reports

  • ST-103 - Drug Profile
  • ST-103 - Drug Profile

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are ##, ##, ##, ## and ## respectively.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Product Initiative

PLOS ONE; ##(##): ##-##.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative
  • Research and Development Brief
  • ST-103 - DRUG PROFILE

ROSUVASTATIN IS A STATIN WITH ANTILIPIDEMIC AND POTENTIAL ANTINEOPLASTIC ACTIVITIES.

  • Digestive System Disorder
  • Lipid Modifying Drug
  • United States
  • World
  • Product Initiative
  • EVOLOCUMAB - DRUG PROFILE

FH is one of the most common life-threatening genetic diseases, affecting between ## in ## and ## in ## people (##. ##-##. ## per cent).

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • EVOLOCUMAB - DRUG PROFILE

Phase III - Trial Details EVOLOCUMAB - DRUG PROFILE Product Description Evolocumab (AMG-##, Repatha) is a monoclonal antibody acts as lipid modifying agent.

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • BEZAFIBRATE ER - DRUG PROFILE
  • EVOLOCUMAB - DRUG PROFILE

Bezafibrate is an agonist of peroxisome proliferator-activated receptor alpha (PPARalpha) with antilipidemic activity.

  • Endocrine Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

Ezetimibe act as an inhibitor of Sterol O-acyltransferase ## and Niemann-Pick C##-like protein ##.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Company Operations
  • Product Initiative

AS A RESULT, PHYSICIANS MAY EXPECT SIMILARLY STRINGENT STUDIES FOR NEW LIPID-MODIFYING DRUG THERAPIES.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • AND APO B GENE SILENCERS

THE NUMBER OF MOLECULES IN FIGURE ##. ## BELOW IS MORE THAN ## OWING TO THE CO-DEVELOPMENT OF SOME MOLECULES BY MULTIPLE COMPANIES, IN WHICH CASE THE MOLECULE HAS BEEN COUNTED SEPARATELY FOR EACH DEVELOPER. ## FIGURE ##. ## PIPELINE ANALYSIS: DISTRIBUTION BY DRUG DEVELOPER ## ##

  • Lipid Modifying Drug
  • United States
  • Demand
  • Pfizer Inc.
  • Sanofi S.A.